• Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line 

      Kreutzman, Anna; Yadav, Bhagwan; Brümmendorf, Tim H.; Gjertsen, Bjørn Tore; Lee, Moon Hee; Janssen, Jeroen; Kasanen, Tiina; Koskenvesa, Perttu; Lofti, Kourosh; Markevärn, Berit; Olsson-Strömberg, Ulla; Stentoft, Jesper; Stenke, Leif; Söderlund, Stina; Udby, Lene; Richter, Johan; Hjorth-Hansen, Henrik; Mustjoki, Satu (Journal article; Peer reviewed, 2019)
      Changes in the immune system induced by tyrosine kinase inhibitors (TKI) have been shown to positively correlate with therapy responses in chronic myeloid leukemia (CML). However, only a few longitudinal studies exist and ...
    • Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia 

      Malani, Disha; Kumar, Ashwini; Brück, Oscar; Kontro, Mika; Yadav, Bhagwan; Hellesøy, Monica; Kuusanmäki, Heikki; Dufva, Olli; Kankainen, Matti; Eldfors, Samuli; Potdar, Swapnil; Saarela, Jani; Turunen, Laura; Parsons, Alun; Västrik, Imre; Kivinen, Katja; Saarela, Janna Saija; Räty, Riikka; Mooij, Wolf M.; Lehto, M; Gjertsen, Bjørn Tore; Mustjoki, Satu; Aittokallio, Tero Antero; Wennerberg, Krister; Heckman, Caroline Akemi; Kallioniemi, Olli; Porkka, Kimmo (Journal article; Peer reviewed, 2021)
      We generated ex vivo drug-response and multiomics profiling data for a prospective series of 252 samples from 186 patients with acute myeloid leukemia (AML). A functional precision medicine tumor board (FPMTB) integrated ...